Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Biostock: PHI comments on expansion into veterinary IVF
Phase Holographic Imaging is broadening its focus. The company, which previously operated in regenerative medicine and cell therapy, is now adding the fast-growing field of in vitro fertilization, IVF, for livestock to its pipeline. BioStock contacted CEO Patrik Eschricht to learn more about the decision and what opportunities he sees with the new venture.
PHI sets sights on IVF applications in livestock
Phase Holographic Imaging PHI AB (“PHI” or the “Company”), a leading provider of advanced holographic imaging solutions, announces its strategic expansion into in vitro fertilization (IVF) in livestock – a growing field where advanced imaging can improve the assessment of oocytes and embryos in livestock breeding. The initiative leverages PHI’s core Quantitative Phase Imaging (QPI) technology and will explore how label-free, non-invasive imaging can make IVF in cows and horses more consistent, efficient, and scalable. PHI’s next-generation HoloMonitor®, which the new IVF-initiative is based on, is set to be launched later this year and PHI has officially filed a trademark application for HoloOocyte.
Interim Report 1 2025/26
The first quarter of the fiscal year marks a pivotal moment for PHI as we continue to build momentum across our strategic pillars. Our commitment to innovation, clinical integration, and global expansion remains steadfast, and the progress made this quarter reflects the dedication and ingenuity of our entire team.
Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)
The shareholders of Phase Holographic Imaging PHI AB (publ), reg.no. 556542-7811, are hereby invited to attend the annual general meeting on 16 October 2025 at 3 p.m. at the company´s office at Skiffervägen 48 in Lund.
PHI provides an update regarding the development progress of the new generation of HoloMonitor®
Phase Holographic Imaging PHI AB (“PHI” or the “Company”), a leading provider of advanced holographic imaging solutions, is pleased to update the market on the development progress of its next-generation of HoloMonitor®, which is scheduled for launch before the end of 2025. With the forthcoming launch of the new generation of HoloMonitor®, the Company will be moving into more clinically focused applications and a new, larger market segment.
Singapore
Phase Holographic Imaging Signs New Distributor for Singapore and Malaysia
Phase Holographic Imaging PHI AB (“PHI” or the “Company”), is proud to announce the appointment of a new distributor, Gaia Bioscience Pte Ltd, for Singapore and Malaysia. This strategic partnership marks a significant step in PHI’s expansion into Southeast Asia, strengthening and accelerating its presence in one of the world’s most dynamic life science markets.
Interim Report 4 2024/25
This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
Biostock: PHI’s CEO comments on the proposed new distribution strategy
Phase Holographic Imaging is set to redefine its global distribution strategy by amending its agreement with Altium, its primary distributor and major shareholder. By convening an Extraordinary General Meeting to ratify these changes, PHI signals a decisive move toward enhanced commercial autonomy and accelerated growth. We spoke with PHI’s CEO, Patrik Eschricht, to learn more.
Phase Holographic: Proposal to amend the Altium Distribution Agreement
Phase Holographic Imaging PHI AB (“PHI” or the “Company”) announces that the Board of Directors has decided to call for an Extraordinary General Meeting to approve a proposed amendment of the distribution agreement with Altium SA (“Altium”), the Company’s global distributor and main shareholder.